IP Library Granted Patent US 7,763,081
Granted Patent B2
US 7,763,081 · App. 11/049,291 · Granted Jul 27, 2010

Tissue graft

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,763,081
App. No.
11/049,291
Granted
Jul 27, 2010
Kind
B2
Abstract

The present invention relates to a method of preparing a tissue graft material. The invention also relates to a multipurpose tissue graft material and to methods of using same as a replacement for vascular and non-vascular tissue.

Claims (21)

1. A method of preparing an arteriovenous graft consisting essentially of:

i) washing a starting tissue obtained from a human or animal ureter with at least one bioburden reducing agent so that said starting tissue is disinfected,

ii) decellularizing the disinfected tissue resulting from step (i) with a solution that lyses cells of said disinfected tissue so that a decellularized tissue matrix is formed,

iii) contacting said decellularized tissue matrix resulting from step (ii) with at least one nuclease so that nucleic acid associated with said decellularized tissue matrix is degraded, and

iv) washing said decellularized, nuclease-treated tissue matrix resulting from step (iii) so that cellular or extracellular debris is removed and said arteriovenous graft is obtained.

2. The method according to claim 1 wherein said at least one bioburden reducing agent is an antimicrobial agent.

3. The method according to claim 1 wherein, in step (ii), sterile water is used to decellularize the disinfected tissue resulting from step (i).

4. The method according to claim 1 wherein, in step (ii), an aqueous hypotonic buffer is used to decellularize the disinfected tissue resulting from step (i).

5. The method according to claim 1 wherein, after step (iv), said arteriovenous graft is sterilized.

6. The method according to claim 1 wherein, after step (iv), said arteriovenous graft is cryopreserved.

7. An unfixed decellularized arteriovenous graft produced by a method consisting essentially of the steps of:

i) washing a starting tissue obtained from a human or animal ureter with at least one bioburden reducing agent so that said starting tissue is disinfected,

ii) decellularizing the disinfected tissue resulting from step (i) with sterile water or an aqueous hypotonic buffer that lyses cells of said disinfected tissue so that a decellularized tissue matrix is formed,

iii) contacting said decellularized tissue matrix resulting from step (ii) with at least one nuclease so that nucleic acid associated with said decellularized tissue matrix is degraded, and

iv) washing said decellularized, nuclease-treated tissue matrix resulting from step (iii) so that cellular or extracellular debris is removed and said arteriovenous graft is produced.

8. A method of treating a patient in need of an arteriovenous graft comprising introducing into said patient an unfixed, decellularized arteriovenous graft that is obtained by the method according to claim 1 .

9. A method of treating a patient having a defective vein or artery comprising replacing said defective vein or artery with said arteriovenous graft according to claim 7 .

10. The method according to claim 9 wherein said patient has a defective vein.

11. The method according to claim 9 wherein said patient has a defective artery.

12. The method according to claim 1 wherein said at least one nuclease is DNAse I and RNAse A.

13. The arteriovenous graft according to claim 7 wherein said at least one nuclease is DNAse I and RNAse A.

Assignments (5)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 22, 2024
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: CRYOLIFE, INC.; ON-X LIFE TECHNOLOGIES, INC.
Reel/Frame 066360/0562 →
PATENT SECURITY AGREEMENT Recorded Dec 1, 2017
From: CRYOLIFE, INC.; ON-X LIFE TECHNOLOGIES, INC. (F/K/A MCRI, INC.)
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 044616/0940 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Dec 1, 2017
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS ADMINISTRATIVE AGENT
To: CRYOLIFE, INC.; CRYOLIFE ACQUISITION CORPORATION; CARDIOGENESIS CORPORATION (N/K/A CRYOLIFE, INC.); HEMOSPHERE, INC.; ON-X LIFE TECHNOLOGIES, INC. (F/K/A MCRI, INC.); VALVE SPECIAL PURPOSE CO., LLC
Reel/Frame 044621/0240 →
SECURITY INTEREST Recorded Jan 21, 2016
From: CRYOLIFE, INC., AS GRANTOR; VALVE SPECIAL PURPOSE CO., LLC, AS GRANTOR; ON-X LIFE TECHNOLOGIES, INC., AS GRANTOR
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS AGENT
Reel/Frame 037569/0212 →
ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 19, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
Reel/Frame 037146/0466 →